Diffuse large B cell lymphoma
Conditions
Interventions
Sponsors
Beijing Hospital
Eligibility
Sex/Gender
All
Age
60 Years to 120 Years
Inclusion criteria
Inclusion criteria: 1) CD20-positive diffuse large B-cell lymphoma confirmed by reference to the 5th edition of the World Health Organization (WHO) classification of neoplasms of the hematopoietic and lymphoid tissues; 2) Prior treatment with rituximab-containing therapy; 3) Age = 60 years; 4) Presence of at least one measurable lesion; 5) The patient has received or is expected to receive a polatuzumab vedotin-based regimen; 6) The patient voluntarily agrees to participate in the study and signs an informed consent form.
Exclusion criteria
Exclusion criteria: Patients or family member refuses to participate in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall response rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| 2-year overall survival rate;2-year progression-free survival rate;Adverse events; | — |
Countries
China
Contacts
Public ContactBai Jie-fei
Beijing Hospital
Outcome results
None listed